Soliris (eculizumab)

pCPA File Number: 21270

Negotiation Status:

Concluded without agreement

Indication(s):

Neuromyelitis optica spectrum disorder (NMOSD)

Sponsor/Manufacturer:

Alexion Pharma Canada Corp.

CDA-AMC Project Number:

SR0640-000

pCPA Engagement Letter Issued:

2021-03-02

Negotiation Process Concluded:

2022-12-12